Sigrid Therapeutics granted European patent covering the use of porous SiPore® silica particles as pharmaceutical or dietary active ingredients

By March 7, 2022 No Comments

Stockholm, Sweden March 7, 2022. Sigrid Therapeutics, a Swedish healthtech company specializing in the prevention and treatment of type-2 diabetes and obesity, today announced that the European Patent Office has granted the company patent EP2916852 titled “A porous silica material for use as a pharmaceutical or dietary active ingredient”. The patent supports use of Sigrid’s breakthrough, mesoporous silica particles (MSP)-based device which consists of precisely engineered micron-sized silica particles with tailored porosity designed to act locally in the gut as a pharmaceutical and dietary active ingredient. Covering the EU, UK, Switzerland, Norway, Iceland and Turkey, the European patent follows similar grants in the US, Canada, Australia, Japan and Israel and significantly strengthens Sigrid’s IP portfolio.

Dr. Ghislaine Robert Nicoud, Material Researcher & IP Manager, Sigrid Therapeutics commented:

“This European patent marks the start of a breakthrough year for Sigrid as we look to start our pivotal clinical trial SHINE in obese and overweight individuals with higher-than-normal blood sugar levels. We have secured manufacturing capacity and are attracting growing interest worldwide from opinion leaders representing both the medical and nutritional fields.”

For more information, please contact:
Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics

Phone +46 72 389 3396,


About Mesoporous silica particles (MSP)
Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes. Studies in mice, published in Nanomedicine1,2 have shown that MSP induced weight loss in obese mice and that food efficiency was reduced by 33% leading to a positive effect on metabolic profile with significant lower levels of adipose tissue formation and leptin, together with lower levels of circulating insulin. Weight gain was thus sufficiently attenuated. Further in vivo studies have shown that MSP led to reduced lipid adsorption in a post-prandial model3. Additional pre-clinical results published in Advanced Healthcare Materials4 confirm these findings and are compatible with a mode of action whereby a portion of the enzymes are trapped inside the MSPs resulting in an enzyme-blocking effect reducing the break down food and thus reduce the energy uptake into the body.

About Sigrid Therapeutics
Sigrid Therapeutics (Sigrid) is a clinical-stage technology startup pioneering a new class of naturally sourced, carefully engineered porous minerals to prevent and treat metabolic disease and disorders, including type 2 diabetes. The Company’s lead product candidate, SiPore21®, is an orally-administered medical device based on the Company’s proprietary platform technology, SiPore®. Designed to act locally in the gut, SiPore®, consists of precisely engineered micron-sized silica particles with tailored porosity. Clinical data confirms SiPore®’s beneficial effects on a range of metabolic parameters and its excellent safety profile4-7. Upon its approval, SiPore21® will be the first medical device available for reduction of blood sugar levels in people at risk of developing type 2 diabetes.

  1. Large pore mesoporous silica induced weight loss in obese mice, Nanomedicine, 2014,
  2. Mesoporous Silica with Precisely Controlled Pores Reduces Food Efficiency and Suppresses Weight Gain in Mice, Nanomedicine, 2020,
  3. Towards mesoporous silica as a pharmaceutical treatment for obesity – impact on lipid digestion and absorption, European Journal of Pharmaceutics and Biopharmaceutics, 2022,
  4. Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans, Advanced Healthcare Materials, 2020,
  5. Engineered Silica Particles Work as a Molecular Sieve and Reduce Metabolic Risk Factors in Obese Male Volunteers, presented at the ADA 2019 Scientific Session, available on:
  6. Oral intake of mesoporous silica is safe and well tolerated in male humans, PLoS ONE, 2020, DOI: 10.1002/adhm.202000057
  7. Engineered mesoporous silica reduces long-term blood glucose, HbA1c, and improves metabolic parameters in prediabetics, Nanomedicine, 2021,

Leave a Reply